Avalanche Biotechnologies to Present at Upcoming Investor Conferences
- Cowen and Company’s 36th Annual
Health Care Conference onWednesday, March 9 at9:20 a.m. ET inBoston , and - Alliance for Regenerative Medicine’s 4th Annual Cell and Gene Therapy Investor Day on
Tuesday, March 22 at4:50 p.m. ET inNew York .
A recorded webcast of Mr. Cleveland’s presentation at the
About
Avalanche is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients suffering from chronic or debilitating disease. Avalanche is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. With significant capabilities and expertise in vector optimization, process development and manufacturing, Avalanche seeks to discover and develop targets in ophthalmology and beyond.
ContactsLauren Glaser , Head of Investor Relations (650) 656-9347 lauren@avalanchebiotech.com